{
    "id": 1389,
    "fullName": "ERBB3 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) amp indicates an increased number of copies of the ERBB3 (HER3) gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "amp",
    "createDate": "08/12/2014",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20339,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer harboring MET D1010H treated with Capmatinib (INC280) demonstrated resistance and was found via tissue testing to have acquired EGFR amplification and ERBB3 (HER3) amplification and via plasma testing to have acquired MET D1228N (PMID: 32034073).",
            "molecularProfile": {
                "id": 35131,
                "profileName": "EGFR amp ERBB3 amp MET D1010H MET D1228N"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20351,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung cancer patient with ERBB3 (HER3) amplification, MET amplification, and MET D1010N demonstrated a partial response for 13.3 months when treated with Xalkori (crizotinib) (PMID: 32034073).",
            "molecularProfile": {
                "id": 35147,
                "profileName": "ERBB3 amp MET D1010N MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20354,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung cancer patient with MET D1010N, MET amplification, and ERBB3 (HER3) amplification initially responded to Xalkori (crizotinib), but then progressed, and was found via tissue testing and plasma testing to have acquired CCND1 amplification (PMID: 32034073).",
            "molecularProfile": {
                "id": 35150,
                "profileName": "CCND1 amp ERBB3 amp MET D1010N MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20356,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung cancer patient harboring CCDN1 amplification, KRAS G60D, and MET D1010N via plasma testing demonstrated stable disease for 3.8 months when treated with Glesatinib (MGCD265), but then progressed, and plasma testing revealed acquisition of ERBB3 (HER3) amplification (PMID: 32034073).",
            "molecularProfile": {
                "id": 35153,
                "profileName": "CCND1 amp ERBB3 amp KRAS G60D MET D1010N"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1412,
            "profileName": "ERBB3 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 4407,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB3 amp"
                },
                {
                    "id": 14007,
                    "name": "HER2 (ERBB2) Vaccine",
                    "profileName": "ERBB3 amp"
                },
                {
                    "id": 4239,
                    "name": "HER2 (ERBB2) Antibody",
                    "profileName": "ERBB3 amp"
                },
                {
                    "id": 4241,
                    "name": "HER3 (ERBB3) Antibody",
                    "profileName": "ERBB3 amp"
                },
                {
                    "id": 4238,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB3 amp"
                },
                {
                    "id": 4240,
                    "name": "HER3 Inhibitor",
                    "profileName": "ERBB3 amp"
                }
            ]
        },
        {
            "id": 35131,
            "profileName": "EGFR amp ERBB3 amp MET D1010H MET D1228N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35147,
            "profileName": "ERBB3 amp MET D1010N MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35150,
            "profileName": "CCND1 amp ERBB3 amp MET D1010N MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35153,
            "profileName": "CCND1 amp ERBB3 amp KRAS G60D MET D1010N",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}